Elevance Health, Inc. $ELV Stake Increased by CenterBook Partners LP

CenterBook Partners LP boosted its stake in Elevance Health, Inc. (NYSE:ELV) by 20.2% during the 3rd quarter, HoldingsChannel reports. The fund owned 12,078 shares of the company’s stock after buying an additional 2,033 shares during the period. CenterBook Partners LP’s holdings in Elevance Health were worth $3,903,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ELV. Physician Wealth Advisors Inc. lifted its position in shares of Elevance Health by 331.6% during the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the last quarter. Activest Wealth Management increased its holdings in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares during the last quarter. Vermillion & White Wealth Management Group LLC raised its stake in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after buying an additional 37 shares in the last quarter. BOK Financial Private Wealth Inc. acquired a new stake in Elevance Health during the second quarter valued at approximately $32,000. Finally, Motco lifted its holdings in Elevance Health by 334.8% during the 3rd quarter. Motco now owns 100 shares of the company’s stock worth $32,000 after buying an additional 77 shares during the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Price Performance

Shares of NYSE ELV opened at $346.31 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.54. The firm has a market capitalization of $76.43 billion, a PE ratio of 13.79, a P/E/G ratio of 1.92 and a beta of 0.50. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75. The business’s fifty day moving average price is $352.94 and its two-hundred day moving average price is $333.33.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the prior year, the firm earned $3.84 earnings per share. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.0%. Elevance Health’s dividend payout ratio (DPR) is 27.23%.

Wall Street Analyst Weigh In

ELV has been the subject of a number of research analyst reports. Weiss Ratings downgraded Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, February 2nd. Leerink Partners lifted their price objective on shares of Elevance Health from $350.00 to $357.00 and gave the stock a “market perform” rating in a report on Thursday, January 29th. Wells Fargo & Company lowered their target price on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Jefferies Financial Group dropped their target price on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a report on Friday, January 30th. Finally, Wolfe Research set a $425.00 price target on shares of Elevance Health and gave the company an “outperform” rating in a report on Thursday, January 8th. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Elevance Health has an average rating of “Moderate Buy” and an average price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.